Elahere (Mirvetuximab soravtansine-gynx) for Ovarian Cancer

Overview
Elahere is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Specifically, Elahere is indicated for use when cancer has failed to respond to up to three previous lines of systemic treatment and is resistant to platinum-based treatment, and cancer cells test positive for folate receptor alpha (FR-alpha) protein. Elahere is also known by its drug name, mirvetuximab soravtansine-gynx.

Elahere is a type of targeted therapy. Elahere is an antibody-drug conjugate consisting of two parts. One part is a biologic drug — a genetically engineered antibody, or immune protein — that targets the FR-alpha protein on cancer cells. The other part is a type of drug called a microtubule inhibitor. In combination, the antibody delivers the drug directly into cancer cells, where it destabilizes the cancer cell and causes its death.

How do I take it?
Elahere is administered as an intravenous infusion once every three weeks. Elahere comes in the form of a single-dose vial.

Side effects
The FDA-approved label for Elahere lists common side effects including vision impairment, damage to the cornea of the eye, dry eye, eye inflammation, sensitivity to light, fatigue, nausea, abdominal pain, peripheral neuropathy (numbness or pins and needles sensations), diarrhea, constipation, and changes in blood levels.

Rare but serious side effects listed for Elahere can include pneumonitis (lung inflammation), severe visual impairment, and fetal harm.

For more details about this treatment, visit:

Elahere — ImmunoGen
https://www.elahere.com